Broker Recommendations
Berenberg upgrades Moneysupermarket, cites attractive entry point
Berenberg upgraded Moneysupermarket on Thursday to ‘buy’ from ‘hold’ and lifted the price target to 295p from 290p, citing an attractive entry point.
Berenberg raises target price on Barclays
Analysts at Berenberg raised their target price on banking giant Barclays from 240. 0p to 270. 0p on Wednesday, stating the stock's current level of returns remains "chronically undervalued".
Centrica shares are cheap after recent weakness, says JPMorgan
JPMorgan has maintained an 'overweight' position on energy and services company Centrica, saying the stock's current valuation is "undemanding" given recent weakness.
Jefferies upgrades Genel to ‘buy’, lifts price target
Jefferies upgraded Genel to ‘buy’ from ‘hold’ on Wednesday and lifted the price target to 100p from 85p.
Canaccord Genuity slightly raises target price on Arrow Exploration
Analysts at Canaccord Genuity hiked their target price on exploration and production business Arrow Exploration from 40. 0p to 44. 0p on Tuesday following "a very encouraging start" to the group's extensive 2024 drilling programme.
Berenberg lowers target price on XP Power
Analysts at Berenberg lowered their target price on power supply solutions group XP Power from 1,700. 0p to 1,400. 0p on Tuesday but said its thesis on the stock was unchanged.
Jefferies upgrades Domino’s Pizza to ‘buy’
Jefferies upgraded Domino’s Pizza Group on Tuesday to ‘buy’ from ‘hold’ and lifted the price target to 430p from 410p.
Citi stays at 'buy' on Centrica
Analysts at Citi reiterated their 'buy' rating on energy and services company Centrica on Monday following the publication of the group's full-year results.
Berenberg hikes Flutter target price, reiterates 'buy'
Berenberg lifted its price target on Flutter Entertainment to 18,600p from 17,000p on Monday and reiterated its ‘buy’ recommendation, as it highlighted strong growth and balance sheet flexibility.
Berenberg slashes Close Brothers price target amid ‘regulatory rollercoaster’
Berenberg slashed its price target on Close Brothers on Friday to 425p from 1,100p as it cut estimates after the merchant bank announced it was scrapping its dividend amid a regulator probe into car financing.
Barclays starts coverage of Dowlais at 'overweight'
Barclays initiated coverage of Dowlais on Friday with an ‘overweight’ rating and 110p price target.
Berenberg hikes target price on GSK
Analysts at Berenberg hiked their target price on drugmaker GSK from £16. 50 to £18. 20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.
Citi upgrades Kingfisher to ‘buy’ from ‘neutral’
Citi upgraded B&Q and Castorama owner Kingfisher on Thursday to ‘buy’ from ‘neutral’ as it argued the UK housing recovery supports a re-rating.
JPMorgan sees scope for Auto Trader to underperform
JPMorgan Cazenove struck a cautious note on the outlook for Auto Trader on Thursday as it took a look at the UK automotive retail sector.
RBC Capital upgrades Transact owner IntegraFin to ‘outperform’
RBC Capital Markets upgraded Transact owner IntegraFin Holdings on Thursday to ‘outperform’ from ‘sector perform’ and lifted the price target to 330p from 280p.
Deutsche Bank upgrades Wizz Air, hikes price target
Deutsche Bank upgraded Wizz Air to ‘hold’ from ‘sell’ on Wednesday and hiked the price target to 2,300p from 1,800p.
Canaccord Genuity lowers target price on Synthomer
Analysts at Canaccord Genuity lowered their target price on chemicals business Synthomer from 350. 0p to 300. 0p on Wednesday as it effectively pushed out its expectations for the group's recovery by 12 months.
RBC Capital starts discoverIE at ‘sector perform’
RBC Capital Markets initiated coverage of discoverIE on Wednesday with a ‘sector perform’ rating and 760 price target, as it said the growth outlook remains strong, but less differentiated.
RBC Capital starts Breedon at ‘outperform’
RBC Capital Markets initiated coverage on construction materials group Breedon on Tuesday with an ‘outperform’ rating and 575p price target.
Citi ups recommendation on GSK to 'buy'
Citi has upgraded its rating on vaccines and drugs blue chip GSK to ‘buy' while also boosting its earnings estimates.